Friedreich’s Ataxia: Film Premiere
I – Introduction
Friedreich’s Ataxia (FA) is a degenerative neuro-muscular disorder that affects approximately 1/50,000 people in the United States. FA can start anywhere from childhood to adulthood. There is loss of muscle strength and coordination. Those patients diagnosed with FA at a young age require mobility aids, such as a wheelchair, walker, or cane by their teens or early 20’s. There are currently no approved treatments for FA.
II – Documentary Premier: The Ataxian
Kyle Bryant, a spokesperson for the organization, Friedreich’s Ataxia Research Alliance (FARA), led a team of bicyclists in a race across America. Two Redwood Creek Entertainment filmmakers, Kevin Schlanser and Zack Bennett, decided to follow Kyle’s participation in the tough race. This resulted in a feature-length documentary titled, “The Ataxian”.
The World Premiere of the film is scheduled for this Saturday, June 6th, at the Dances With Films festival in Hollywood, California, at the TCL Chinese 6 Theaters.
The film’s social media information:
III – FDA Orphan Drug Designations For FA
The chart below identifies FDA Orphan Drug Designations (ODDs) for FA in ascending ODD Date order:
|Generic Name/ODD Date||Sponsor Company||Indication|
|1||Physostigmine salicylatephysostigmine salicylate/ 01.16.85||Forest Pharmaceutical||FA & other inherited ataxias|
|2||Idebenone/ 03.25.04||Santhera Pharmaceuticals||FA|
|4||N-(6-2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide/ 05.17.10||Repligen Corporation||FA|
|5||Coenzyme Q10 and d-alpha-tocopherol/ 03.14.11||NBI Pharmaceuticals||FA|
|6||Interferon gamma/ 11.04.11||Roberto Testi, MD (Italy)||FA|
|7||Dimethyl fumarate/ 09.11.13||Gino Cortopassi, USA||FA|
|8||Vatiquinone/ 01.31.14||Edison Pharmaceuticals||FA|
|9||Interferon Gamma-1b/ 10.01.14||Horizon Pharma (Ireland)||FA|
Please Note: Movie Logo courtesy of Redwood Creek Entertainment.
Copyright © 2012-2015, Orphan Druganaut Blog. All rights reserved.